Equities analysts expect that Nextgen Healthcare Inc (NASDAQ:NXGN) will post sales of $130.79 million for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Nextgen Healthcare’s earnings. The lowest sales estimate is $129.10 million and the highest is $133.23 million. Nextgen Healthcare reported sales of $131.72 million in the same quarter last year, which would suggest a negative year over year growth rate of 0.7%. The firm is expected to announce its next earnings results on Thursday, January 24th.

According to Zacks, analysts expect that Nextgen Healthcare will report full-year sales of $530.38 million for the current year, with estimates ranging from $527.40 million to $532.94 million. For the next fiscal year, analysts expect that the business will report sales of $555.34 million, with estimates ranging from $529.40 million to $565.83 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Nextgen Healthcare.

Nextgen Healthcare (NASDAQ:NXGN) last posted its earnings results on Tuesday, October 30th. The company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.05. The business had revenue of $130.30 million during the quarter, compared to the consensus estimate of $134.55 million. Nextgen Healthcare had a return on equity of 10.23% and a net margin of 1.17%. Nextgen Healthcare’s revenue was down 1.7% on a year-over-year basis. During the same quarter last year, the company earned $0.22 EPS.

Several equities analysts recently commented on the company. Morgan Stanley upgraded Nextgen Healthcare from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $12.00 to $16.00 in a research report on Thursday, November 1st. Zacks Investment Research upgraded Nextgen Healthcare from a “sell” rating to a “hold” rating in a research report on Monday, December 31st. Dougherty & Co upgraded Nextgen Healthcare from a “neutral” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Friday. TheStreet downgraded Nextgen Healthcare from a “b-” rating to a “c+” rating in a research report on Wednesday, November 21st. Finally, KeyCorp cut their price objective on Nextgen Healthcare from $17.00 to $16.00 and set an “underweight” rating for the company in a research report on Wednesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $18.50.

Shares of Nextgen Healthcare stock traded up $0.55 during midday trading on Friday, hitting $16.66. 402,149 shares of the company were exchanged, compared to its average volume of 314,781. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market capitalization of $1.03 billion, a PE ratio of 29.23, a price-to-earnings-growth ratio of 3.15 and a beta of 1.07. Nextgen Healthcare has a 52 week low of $12.24 and a 52 week high of $23.73.

A number of institutional investors and hedge funds have recently modified their holdings of NXGN. Bank of Montreal Can acquired a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at $165,000. BlueMountain Capital Management LLC acquired a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at $205,000. Quantbot Technologies LP acquired a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at $207,000. Hanson & Doremus Investment Management acquired a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at $208,000. Finally, Piedmont Investment Advisors Inc. acquired a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at $222,000. Hedge funds and other institutional investors own 68.73% of the company’s stock.

Nextgen Healthcare Company Profile

NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.

Featured Article: How to invest in a bear market

Get a free copy of the Zacks research report on Nextgen Healthcare (NXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nextgen Healthcare (NASDAQ:NXGN)

Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.